M&A

News

23andMe founder Anne Wojcicki is hoping to make a fresh bid for the genetic testing firm, riding out a takeover deal with Regeneron.

News

Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM.

News

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

News

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.

News

DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.

News

BioMarin has made its first M&A play under James Sabry, buying Inozyme to flesh out its enzyme replacement therapies (ERTs) for rare diseases.